Physician profile
James Lust
NPI 1831116466
$29,926.64
in general payments reported to CMS, 2019-2025
67 companies · $2,653 in 2025
The $2,653 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,111 · 2022: $7,188 · 2023: $7,599 · 2024: $8,376 · 2025: $2,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,788 · Travel and Lodging: $512 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,149.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,787.50 |
| Travel and Lodging | $511.74 |
| Education | $179.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,920.07 | 2021-2025 | |
| Biogen, INC. | $1,821.17 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,460.63 | 2021-2024 | Austedo Xr, Ajovy |
| Emd Serono, INC. | $978.47 | 2022-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $946.88 | 2021-2025 | |
| Eisai INC. | $931.41 | 2021-2025 | |
| Celgene Corporation | $911.71 | 2021-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $889.98 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $860.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $836.44 | 2021 | |
| Amgen INC. | $828.71 | 2021-2024 | Aimovig, Uplizna |
| Boston Scientific Corporation | $704.18 | 2024-2025 | General - Dbs |
| Ucb, INC. | $702.12 | 2021-2025 | Rystiggo, Briviact, Nayzilam |
| Pfizer INC. | $698.30 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $654.48 | 2023-2025 | Rexulti, Nuedexta |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $653.76 | 2023-2024 | Wakix |
| Lundbeck LLC | $632.56 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $605.32 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Genentech USA, INC. | $569.08 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| E.R. Squibb & Sons, L.L.C. | $507.25 | 2021-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $507.03 | 2021-2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $456.30 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $385.02 | 2021-2025 | Rytary, Crexont, Lyvispah |
| Argenx US, INC. | $340.60 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $326.57 | 2021-2025 | Ultomiris |
| Horizon Therapeutics Plc | $302.00 | 2021-2023 | Uplizna |
| Impel Pharmaceuticals INC. | $257.11 | 2022-2023 | Trudhesa |
| Neurelis, INC. | $243.40 | 2023-2025 | Valtoco |
| Genzyme Corporation | $203.78 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $202.87 | 2022-2023 | Ponvory |
| Idorsia Pharmaceuticals US INC | $175.65 | 2022-2024 | Quviviq |
| Merz Pharmaceuticals, LLC | $170.75 | 2021-2024 | Xeomin |
| Neurocrine Biosciences, INC. | $169.40 | 2022-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $152.35 | 2022-2024 | Auvelity |
| Tanabe Pharma America, INC. | $140.58 | 2021-2025 | Radicava |
| Catalyst Pharmaceuticals, INC. | $131.63 | 2022-2025 | Firdapse |
| Adamas Pharmaceuticals, INC. | $98.69 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $93.15 | 2023-2025 | Lumryz |
| Scilex Pharmaceuticals INC. | $87.53 | 2023-2024 | Ztlido |
| Penumbra, INC. | $87.31 | 2023 | Artemis |
| Livanova USA, INC. | $86.61 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ipsen Biopharmaceuticals, INC | $82.47 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $76.47 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $75.28 | 2021-2022 | |
| Allergan, INC. | $74.98 | 2021-2022 | |
| Tg Therapeutics, INC. | $73.52 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $66.39 | 2023-2024 | Acthar |
| Abbott Laboratories | $65.79 | 2023-2024 | Proclaim, Infinity |
| Janssen Biotech, INC. | $60.21 | 2025 | |
| Insightec,INC | $58.21 | 2023-2025 | Exablate |
| Kyowa Kirin, INC. | $55.32 | 2021-2024 | Nourianz |
| Sk Life Science, INC. | $52.97 | 2021-2025 | |
| Life Molecular Imaging Ltd | $48.22 | 2025 | Neuraceq |
| Ge Healthcare | $43.73 | 2024 | |
| Sunovion Pharmaceuticals INC. | $43.69 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $42.47 | 2025 | Motpoly Xr |
| Medtronic, INC. | $40.02 | 2021-2024 | Percept Pc Brainsense |
| Grifols USA, LLC | $33.42 | 2024-2025 | Gamunex-C |
| Ani Pharmaceuticals, INC. | $33.41 | 2025 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $28.48 | 2023 | Aptiom |
| Vanda Pharmaceuticals INC. | $26.89 | 2024 | Ponvory |
| Acorda Therapeutics, INC | $26.87 | 2022 | |
| Resmed Corp | $22.98 | 2024 | |
| Cycle Pharmaceuticals INC | $20.34 | 2025 | Tascenso Odt |
| Azurity Pharmaceuticals, INC. | $17.65 | 2022 | |
| Biodelivery Sciences International, INC. | $14.92 | 2021 | |
| Zogenix INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.